CytoDyn Updates

https://www.cytodyn.com/newsroom/press-releases/detail/595/cytodyn-cancels-webcast-and-live-qa-scheduled-for-today

CytoDyn Cancels Webcast and Live Q/A Scheduled for Today CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.  CCR5 appears to play…

https://www.cytodyn.com/newsroom/press-releases/detail/594/cytodyn-to-hold-webcast-and-live-qa-on-january-13

CytoDyn to Hold Webcast and Live Q/A on January 13 CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.  CCR5 appears to play…

https://www.cytodyn.com/newsroom/press-releases/detail/591/cytodyn-announces-favorable-ruling-granting-injunction

CytoDyn Announces Favorable Ruling Granting Injunction Against Former CRO CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.  CCR5 appears to play…

https://youtu.be/jEZ8BlE6jxA

CytoDyn Investment Community Webcast (December 14, 2021)